Medicxi, RA Capital in $30m series-B for Xenikos

Both VC firms joined the financing round as new investors. The principals of Medicxi and RA Capital will join the Xenikos board of directors.

With the fresh capital, the firm intends to advance the development of its lead compound, T-Guard, including conducting clinical phase-III registration trials in the US and EU, arranging commercial-scale production, and submitting the relevant applications for market approval.

Company
Founded in 2009 and headquartered in Nijmegen, Xenikos develops toxin-loaded anti-T-cell antibodies as a therapeutic tool for resetting the body's immune system in T-cell mediated diseases.

People
Medicxi Ventures – Jon Edwards (principal).
RA Capital – Jake Simson (principal).
Xenikos – Ypke van Oosterhout (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Benelux
• Healthcare
• Netherlands
• Venture